Lymphoma Treatment Market Size, Share & Industry Analysis, By Therapy (Immunotherapy, Targeted Therapy, Chemotherapy, and Others), By Disease Type (Non-Hodgkin Lymphoma, and Hodgkin Lymphoma), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others), and Regional Forecast, 2019-2026 (Includes COVID-19 Business Impact)

                                          
We have updated Lymphoma Treatment Market with respect to COVID-19 Business Impact.
Inquire before buying


This report focuses on the Lymphoma Treatment market and value at the global level, regional level, and company level. From a global perspective, this report represents the overall Lymphoma Treatment market size by analyzing historical data and future prospects. Regionally, this report focuses on several key regions: North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America.


Global Lymphoma Treatment Market: Segment Analysis


The research report includes specific segments by region (country), by Company, by Type, and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2019 to 2029. An in-depth analysis of the segments assists in identifying the different factors that will aid market growth.


Global Lymphoma Treatment Market: Regional Analysis


The research report includes a detailed study of regions of North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America. The report has been curated after observing and studying various factors that determine regional growth such as the economic, environmental, social, technological, and political status of the particular region. Researchers have studied the data of revenue, sales, and manufacturers of each mentioned region. This section analyses region-wise revenue and volume for the forecast period of 2019 to 2029.


Global Lymphoma Treatment Market: Competitive Landscape


This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2019 to 2029.
List of Companies Profiled

Strong and Diversified Lymphoma Portfolio of Key Oncology Market Leaders, to Help these Companies Retain a Leading Position

The competition scenario in this market depicts a fairly intense competition with the presence of prominent market players of oncology with their expanded product portfolio of oncology therapeutics. Numerous major market players like Takeda Pharmaceutical Company Limited and Gilead Sciences, Inc. with its subsidiary Kite Pharma, Inc. have strong existence in the global market. However, other players such as Novartis AG, and Bristol Myers Squibb Company also have promising products in the market, ranging from immunotherapy to targeted therapy.
However, various prominent biopharmaceutical companies such as Spectrum Pharmaceuticals, Inc., are making their presence noticeable in the market with their lymphoma treatment product portfolio particularly aimed at the several forms of lymphoma therapeutics. This is anticipated to positively impact the global market as these companies are poised to gain market share during forecast period through key regulatory approvals.

LIST OF KEY COMPANIES PROFILED:

  
Takeda Pharmaceutical Company Limited
  
AstraZeneca
  
Bayer AG
  
Novartis AG
  
Kite Pharma, Inc. / Gilead Sciences, Inc.
  
Spectrum Pharmaceuticals, Inc.
  
Teva Pharmaceutical Industries Ltd.
  
Bristol Myers Squibb Company
  
Janssen Pharmaceuticals, Inc.
  
Genentech, Inc. (F. Hoffmann-La Roche Ltd)
  
CELGENE CORPORATION (Bristol Myers Squibb Company)
  
Merck & Co., Inc.
  
Kyowa Kirin Co., Ltd.
  
AbbVie Inc.
  
Sanofi
  
Others

KEY INDUSTRY DEVELOPMENTS:

In September 2020, Takeda Pharmaceutical Company Limited announced the expansion of its cell therapy manufacturing capabilities with the opening of a new 24,000 square-foot R&D cell therapy manufacturing facility at its R&D headquarters in Boston, Massachusetts. The facility provides end-to-end research and development capabilities and will accelerate Takeda’s efforts to develop next-generation cell therapies, initially focused on oncology with potential to expand into other therapeutic areas.

The R&D cell therapy manufacturing facility will produce cell therapies for clinical evaluation from discovery through pivotal Phase 2b trials. The current Good Manufacturing Practices (cGMP) facility is designed to meet all U.S., E.U. and Japanese regulatory requirements for cell therapy manufacturing to support Takeda clinical trials around the world.

The proximity and structure of Takeda's cell therapy teams allow to quickly apply what they learn across a diverse portfolio of next-generation cell therapies including CAR NKs, armored CAR-Ts and gamma delta T cells. Insights gained in manufacturing and clinical development can be quickly shared across global research, manufacturing and quality teams, a critical ability in their effort to deliver potentially transformative treatments to patients as fast as possible.

Takeda and MD Anderson are developing a potential best-in-class allogeneic cell therapy product (TAK-007), a Phase 1/2 CD19-targeted chimeric antigen receptor-directed natural killer (CAR-NK) cell therapy with potential for off-the-shelf use being studied in patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Two additional Phase 1 studies of Takeda cell therapy programs were also recently initiated: 19(T2)28z1xx CAR T cells (TAK-940), a next-generation CAR-T signaling domain developed in partnership with Memorial Sloan Kettering Cancer Center (MSK) to treat relapsed/refractory B-cell cancers, and a cytokine and chemokine armored CAR-T (TAK-102) developed in partnership with Noile-Immune Biotech to treat GPC3-expressing previously treated solid tumors.

Takeda’s Cell Therapy Translational Engine (CTTE) connects clinical translational science, product design, development, and manufacturing through each phase of research, development and commercialization. It provides bioengineering, chemistry, manufacturing and control (CMC), data management, analytical and clinical and translational capabilities in a single footprint to overcome many of the manufacturing challenges experienced in cell therapy development.

March 2020 -The U.S. FDA announced the partial clinical hold on the phase I trial of a pipeline candidate titled ACTR707 for lymphoma treatment. The pipeline candidate was to be used in combination with rituximab (Rituxan) for patients with relapsed/refractory B-cell lymphoma from Unum Therapeutics, after the company submitted a safety report.

September 2019 -Novartis announced that its product offering of Kymriah (tisagenlecleucel), used for lymphoma treatment, received routine reimbursement for all the eligible UK patients in the NHS system, after the appraisal from the Scottish Medicines Consortium.

March 2019 -The approval of Kymriah (tisagenlecleucel), to be used for lymphoma treatment, in Japan made the therapeutic, the first ever CAR-T cell therapy authorized by a regulatory agency in Asia.

 

REPORT COVERAGE

The lymphoma treatment market report provides a thorough analysis of the market and focuses on key features such as pipeline analysis, prevalence of lymphoma - by key countries - 2018, key industry developments, regulatory scenario - key regions, analysis of economic burden of non-Hodgkin lymphoma, new product launches, and reimbursement scenario. Additionally, the report provides insights into the lymphoma treatment market trends and highlights key industry developments. In addition to the above-mentioned factors, the report includes several factors that have contributed to the growth of the market over the recent years.

Report Scope & Segmentation

Segmentation

By Therapy

  
Immunotherapy
  
Targeted Therapy
  
Chemotherapy
  
Others

By Disease Type

  
Non-Hodgkin Lymphoma
  
Hodgkin Lymphoma

By Distribution Channel

  
Hospital Pharmacies
  
Retail Pharmacies & Drug Stores
  
Online Pharmacies

By Geography

  
North America (U.S. and Canada)
  
Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
  
Asia-Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia-Pacific)
  
Latin America (Brazil, Mexico, and the Rest of Latin America)
  
Middle East & Africa (South Africa, GCC, and the Rest of Middle East & Africa)